SELENOI (EPT1-HUMAN) - The Potential Drug Target and Biomarker

Target Name: SELENOI

NCBI ID: G85465

SELENOI

SELENOI (EPT1-HUMAN) - The Potential Drug Target and Biomarker

Selenoi is a protein that is expressed in the endoplasmic reticulum (ER) and is involved in the regulation of the transport of various proteins into the cell. One of the unique aspects of Selenoi is its ability to interact with the protein EPT1, which is a transmembrane protein that is involved in the intracellular signaling pathway known as the TGF-β pathway. This interaction between Selenoi and EPT1 has led to the hypothesis that selenoi may be a drug target and biomarker for the treatment of various diseases.

The TGF-β pathway is a critical signaling pathway that is involved in the regulation of cell growth, differentiation, and survival. The pathway is activated by the presence of TGF-β ligand, which is a protein that can interact with the EPT1 protein. This interaction between TGF-β and EPT1 leads to the activation of various downstream signaling pathways, including the PI3K/Akt signaling pathway.

The PI3K/Akt signaling pathway is involved in the regulation of various cellular processes, including cell survival, angiogenesis, and inflammation. It is a validated drug target for the treatment of various diseases, including cancer, cardiovascular disease, and neurological disorders.

Selenoi Interacts with EPT1: A Potential Drug Target

The interaction between Selenoi and EPT1 has led to the hypothesis that Selenoi may be a drug target for the treatment of diseases that are characterized by the over-activation of the TGF-β pathway. The over-activation of the TGF-β pathway has been implicated in the development and progression of various diseases, including cancer, neurodegenerative diseases, and cardiovascular disease.

Selenoi has been shown to interact with EPT1 and can inhibit the activity of the TGF-β ligand in the presence of EPT1. This interaction between Selenoi and EPT1 suggests that Selenoi may be a drug target that can be targeted with small molecules or other therapeutic agents.

Selenoi is a protein that is expressed in the ER and is involved in the regulation of protein transport into the cell. It has been shown to interact with various proteins, including EPT1, and to play a role in the regulation of the TGF-β pathway. These interactions suggest that Selenoi may be a biomarker for the treatment of diseases that are characterized by the over-activation of the TGF-β pathway.

Biomarker Potential: The Potential for Selenoi as a Drug Target

The interaction between Selenoi and EPT1 has led to the hypothesis that Selenoi may be a drug target for the treatment of diseases that are characterized by the over-activation of the TGF-β pathway. The over-activation of the TGF-β pathway has been implicated in the development and progression of various diseases, including cancer, neurodegenerative diseases, and cardiovascular disease.

Selenoi has been shown to interact with EPT1 and can inhibit the activity of the TGF-β ligand in the presence of EPT1. This interaction between selenoi and EPT1 suggests that selenoi may be a drug target that can be targeted with small molecules or other therapeutic agents.

In addition to its potential as a drug target, selenoi also has the potential as a biomarker for the diagnosis and monitoring of various diseases. The TGF-β pathway is involved in the regulation of various cellular processes, including cell survival, angiogenesis, and inflammation. It is a validated drug target for the treatment of various diseases, including cancer, cardiovascular disease, and neurological disorders.

Conclusion

In conclusion, the interaction between Selenoi and EPT1 has led to the hypothesis that selenoi may be a drug target and biomarker for the treatment of various diseases characterized by the over-activation of the TGF-β pathway. Further studies are needed to confirm this hypothesis and to determine the most effective method of targeting Selenoi as a drug

Protein Name: Selenoprotein I

Functions: Ethanolaminephosphotransferase that catalyzes the transfer of phosphoethanolamine/PE from CDP-ethanolamine to lipid acceptors, the final step in the synthesis of PE via the 'Kennedy' pathway (PubMed:17132865, PubMed:28052917, PubMed:29500230). PE is the second most abundant phospholipid of membranes in mammals and is involved in various membrane-related cellular processes (PubMed:17132865). The enzyme is critical for the synthesis of several PE species and could also catalyze the synthesis of ether-linked phospholipids like plasmanyl- and plasmenyl-PE which could explain it is required for proper myelination and neurodevelopment (PubMed:29500230)

The "SELENOI Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SELENOI comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets